摘要
目的研究舒尼替尼治疗晚期肾癌的疗效及对生存时间的影响。方法采用随机数字表法将诊断为晚期肾癌的56例患者分为两组,观察组患者接受舒尼替尼治疗,对照组患者接受白细胞介素-2联合干扰素-α治疗。治疗后,参照实体肿瘤疗效评价标准(RECIST)评估治疗效果,治疗前后采集两组患者血清测定血清肿瘤标志物的含量进行分析比较,随访生存时间及生存率。结果化疗后,观察组患者的整体疗效优于对照组,差异有统计学意义(P<0.05);化疗后,观察组患者血清VEGF、CTGF、HIF-1α含量显著低于对照组(P<0.05);随访3年内,观察组患者的OS和PFS均显著长于对照组(P<0.05),1年、2年、3年生存率均显著高于对照组(P<0.05)。结论舒尼替尼治疗晚期肾癌疗效确切,并且能够降低血清肿瘤标志物含量、延长生存时间。
Objective To study the efficacy of sunitinib in the treatment of advanced renal cell carcinoma and its effect on survival time of patients. Methods Fifty-six patients diagnosed as advanced renal cell carcinoma were selected and divided into two groups by random number table. Patients in the observation group received sunitinib treatment, while those in the control group received interleukin-2 com- bined with interferon-α treatment. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Solid Tumors （RECIST）. The serum was collected before and after treatment, and the serum levels of tumor markers were determined. The survival time and survival rate of patients were also analyzed. Results After treatment, the overall effect of observation group were better than that of the control group （P〈0.05）. After therapy, the serum levels of VEGF, CTGF and HIF-1 in observation group were significantly lower than in the control group （P〈0.05）. Within 3 years of follow-up, the overall survival （OS） and progression-free survival （PFS） of observation group were significantly longer than those of control group （P〈0.05）. In addition, the 1-year, 2-year and 3-year survival rate all were significantly higher in observation group than in control group （P 〈 0.05）. Conclusion Sunitinib was effective in the treatment of advanced renal cell car- cinoma. It could lower the levels of tumor markers, and prolong the survival time of patients.
出处
《肿瘤药学》
CAS
2017年第2期195-199,共5页
Anti-Tumor Pharmacy
基金
湖南省卫生厅中医药科研基金资助项目(96602)
关键词
晚期肾癌
舒尼替尼
肿瘤标志物
血管新生
Advanced renal cell carcinoma
Sunitinib
Tumor markers
Angiogenesis
